Related Experiment Video
Updated: Apr 7, 2026
09:37
A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
8.9K
Genetic Interactions Between TRPC6 and NPHS1 Variants Affect Posttransplant Risk of Recurrent Focal Segmental
Summary
A novel TRPC6 mutation causes variable kidney disease, including focal segmental glomerulosclerosis (FSGS). NPHS1 gene variants may influence disease severity and transplant outcomes in families with TRPC6 mutations.
Area of Science:
- Nephrology
- Genetics
- Molecular Biology
Background:
- Transient receptor potential cation channel subfamily member 6 (TRPC6) mutations are linked to focal segmental glomerulosclerosis (FSGS), but disease presentation varies.
- The role of genetic modifiers in TRPC6-associated kidney disease is not fully understood.
Purpose of the Study:
- To investigate the genetic basis for variable TRPC6 mutation phenotypes within a family.
- To explore the functional impact of TRPC6 mutations and NPHS1 polymorphisms on kidney function and transplant outcomes.
Main Methods:
- Family-based genetic analysis of TRPC6 and NPHS1 variants.
- Patch-clamp electrophysiology in HEK293 cells and podocytes to assess TRPC6 channel function.
- In vitro studies examining the interaction between nephrin and TRPC6.
Main Results:
- A novel TRPC6 p.R68W mutation was identified in six family members, with two developing FSGS and renal failure.
- NPHS1 polymorphisms (rs2285450 and rs437168) segregated with renal failure in the family and were more frequent in patients with nephrotic syndrome/FSGS.
- The TRPC6 p.R68W mutation enhanced TRPC6 currents, and the NPHS1 c.294C>T polymorphism impaired nephrin's ability to suppress these currents.
- Cells representing the kidney donor exhibited lower TRPC6 currents compared to the recipient, correlating with clinical outcomes.
Conclusions:
- TRPC6 mutations cause variable kidney disease, influenced by interacting genetic factors like NPHS1 polymorphisms.
- These interactions may explain differing disease penetrance and the lack of FSGS recurrence in the kidney graft of a related living donor transplant.
- TRPC6 and NPHS1 variants are potential therapeutic targets for managing FSGS.
More Related Videos
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
119
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
119
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
136
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
136
01:29Pharmacogenomics: Identification of New Drug Targets
88
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
88
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
69
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
69
01:27Principles of Pharmacogenetics: Types of Genetic Variants
102
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
102
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
69
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69